Arvinas to Participate in Upcoming Investor Conferences
- None.
- None.
NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
- Wells Fargo 2023 Healthcare Conference on Wednesday, September 6. Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
- Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12. Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
- Cantor Global Healthcare Conference on Thursday, September 28. Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
